CN115348968A - 针对淋球菌感染的免疫原性蛋白 - Google Patents

针对淋球菌感染的免疫原性蛋白 Download PDF

Info

Publication number
CN115348968A
CN115348968A CN202080094488.2A CN202080094488A CN115348968A CN 115348968 A CN115348968 A CN 115348968A CN 202080094488 A CN202080094488 A CN 202080094488A CN 115348968 A CN115348968 A CN 115348968A
Authority
CN
China
Prior art keywords
nhba
gonorrhoeae
subject
neisseria
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094488.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·塞布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904450A external-priority patent/AU2019904450A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of CN115348968A publication Critical patent/CN115348968A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
CN202080094488.2A 2019-11-25 2020-11-20 针对淋球菌感染的免疫原性蛋白 Pending CN115348968A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904450A AU2019904450A0 (en) 2019-11-25 Immunogenic protein against gonococcal infection
AU2019904450 2019-11-25
PCT/AU2020/051257 WO2021102505A1 (en) 2019-11-25 2020-11-20 Immunogenic protein against gonococcal infection

Publications (1)

Publication Number Publication Date
CN115348968A true CN115348968A (zh) 2022-11-15

Family

ID=76128579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094488.2A Pending CN115348968A (zh) 2019-11-25 2020-11-20 针对淋球菌感染的免疫原性蛋白

Country Status (10)

Country Link
US (1) US12479892B2 (https=)
EP (1) EP4065595A4 (https=)
JP (2) JP7825273B2 (https=)
KR (1) KR20220152402A (https=)
CN (1) CN115348968A (https=)
AU (1) AU2020390430A1 (https=)
BR (1) BR112022010167A2 (https=)
CA (1) CA3162559A1 (https=)
MX (1) MX2022006299A (https=)
WO (1) WO2021102505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
JP2024526293A (ja) * 2021-07-05 2024-07-17 エヴァクシオン・バイオテック・アクティエセルスカブ 淋菌を標的とするワクチン
WO2025196270A1 (en) 2024-03-22 2025-09-25 Limmatech Biologics Ag Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1373806A (zh) * 1998-05-01 2002-10-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US20180064801A1 (en) * 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
CN107847532A (zh) * 2015-06-02 2018-03-27 由卫生福利和体育大臣代表的荷兰王国 革兰氏阴性菌外膜囊泡抗原表面展示
US20180214531A1 (en) * 2014-07-17 2018-08-02 Glaxosmithkline Biologicals, Sa Meningococcus vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
CN106606775A (zh) 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1373806A (zh) * 1998-05-01 2002-10-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US20180214531A1 (en) * 2014-07-17 2018-08-02 Glaxosmithkline Biologicals, Sa Meningococcus vaccines
CN107847532A (zh) * 2015-06-02 2018-03-27 由卫生福利和体育大臣代表的荷兰王国 革兰氏阴性菌外膜囊泡抗原表面展示
US20180064801A1 (en) * 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ESPOSITO，V. ET AL.: "《Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA)， one of the main antigens of a novel vaccine against Neisseria meningitidis》", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 286, no. 48, 20 September 2011 (2011-09-20), pages 41767 - 41775 *

Also Published As

Publication number Publication date
EP4065595A4 (en) 2023-12-20
EP4065595A1 (en) 2022-10-05
US20230181709A1 (en) 2023-06-15
KR20220152402A (ko) 2022-11-15
JP2023503963A (ja) 2023-02-01
US12479892B2 (en) 2025-11-25
MX2022006299A (es) 2023-01-19
JP7825273B2 (ja) 2026-03-06
AU2020390430A1 (en) 2022-07-14
BR112022010167A2 (pt) 2022-08-09
JP2026021348A (ja) 2026-02-10
CA3162559A1 (en) 2021-06-03
WO2021102505A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
EP2265640B1 (en) Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CN101107007B (zh) 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
CN102834410B (zh) 改性的h因子结合蛋白（fhbp）及其使用方法
JP2026021348A (ja) 淋菌感染症に対する免疫原性タンパク質
KR102761870B1 (ko) 인자 h 결합 단백질 변이체 및 이의 사용 방법
CN105431167A (zh) 非天然发生因子h结合蛋白(fhbp)及其使用方法
WO2009117373A2 (en) Treatment and prevention of gardnerella vaginalis infections
CN103687613A (zh) 蛋白f-具有层粘连蛋白和玻连蛋白结合性能的新的流感嗜血杆菌粘附素
US20140341895A1 (en) PSEUDOMONAS AERUGINOSA OprM EPITOPES FOR USE IN DIAGNOSTICS AND THERAPEUTICS
AU2011284809B2 (en) Recombinant Neisseria meningitidis Por A porin proteins.
Lavender Complement Factor H Related proteins and their biological role during bacterial infection
HK40072982B (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof
HK1186476A (en) Recombinant neisseria meningitidis por a porin proteins
Ispasanie Immune responses to prototype GMMA vaccine against Neisseria meningitidis in Africa
HK1179980A (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof
HK1179980B (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: K. Sebu

Inventor after: E. Shevchenko

Inventor before: K. Sebu

CB03 Change of inventor or designer information